Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Ophthalmology

What Are the Risks of Steroid Eye Drops for VKC?

At a Glance

Steroid eye drops quickly relieve severe vernal keratoconjunctivitis flares but carry serious long-term risks, including silent spikes in eye pressure (glaucoma) and premature cataracts. Doctors use short bursts of steroids for emergencies, then switch to safer daily immunomodulators.

When your child is suffering from a severe flare of vernal keratoconjunctivitis (VKC), steroid eye drops can seem like a miracle. They work quickly and powerfully to calm intense inflammation, relieve severe itching, and reduce swelling [1]. However, you may notice that eye doctors are incredibly cautious about prescribing them, strictly limiting how long they can be used.

This caution is not because the drops don’t work, but because long-term use of steroid eye drops can lead to serious, irreversible eye damage. Unmonitored, extended use of these drops is associated with severe vision-threatening complications, primarily high eye pressure (glaucoma) and cataracts [2][3].

The Major Risks of Long-Term Steroid Use

If steroid eye drops are used for too long or without strict medical supervision, they can cause two major side effects inside the eye:

1. Steroid-Induced Glaucoma (Silent Pressure Spikes)

The most immediate danger of prolonged steroid use is an increase in the pressure inside the eye, known as intraocular pressure (IOP) [4]. In many children and young adults, steroids can cause the fluid inside the eye to build up, leading to steroid-induced glaucoma [2].

This is incredibly dangerous because high eye pressure is “silent.” A child experiencing an eye pressure spike will typically have no pain, redness, or blurry vision to warn you that it is happening. However, if this high pressure continues over time, it can permanently damage the optic nerve, leading to irreversible vision loss [2][5]. This is why any child using steroid eye drops must have their eye pressure checked regularly by an eye doctor [5].

2. Cataract Formation

A cataract is a clouding of the eye’s naturally clear lens, which blurs and distorts vision. While cataracts are normally associated with aging, long-term use of steroid eye drops can cause them to develop prematurely in children and teens [2][4]. Unlike pressure spikes, cataracts are not always “silent”—you or your doctor might eventually notice changes in your child’s vision. While cataract surgery is a highly successful routine procedure, it is best avoided in children whenever possible by limiting steroid exposure.

How Doctors Safely Use Steroids: “Pulse” Therapy

Because of these severe risks, eye doctors have developed a specific, stepwise strategy to get the benefits of steroids while minimizing the danger [1].

During a severe acute flare—when the eye is intensely inflamed, or large bumps (papillae) have formed under the eyelid—doctors will use a short, intense burst of steroid drops. This is often called “pulse” therapy [1][6]. The goal is to aggressively put out the “fire” of the flare-up over a few days or weeks, and then quickly taper the child off the medication [1][7].

Tip: To further reduce risks, you can gently press on the inner corner of your child’s eye (near the nose) for about a minute after applying the drop. This technique, known as punctal occlusion, helps prevent the medicine from draining into the rest of the body.

In some cases, doctors may also prescribe what are known as “soft” steroids, such as loteprednol or fluorometholone. These medications are chemically designed to reduce inflammation but have a lower risk of causing dangerous eye pressure spikes compared to stronger steroids [4]. However, even with “soft” steroids, children must still have their eye pressure checked regularly by an eye doctor to ensure safety [5].

Long-Term Management: Steroid-Sparing Drops

Once the severe flare is under control, the goal is to keep the child off steroids completely. To maintain clear, comfortable eyes over the long term, doctors rely on a different class of medications called immunomodulators (also known as calcineurin inhibitors) [8][9].

Common medications in this class include cyclosporine and tacrolimus [10][11]. These “steroid-sparing” eye drops are not steroids; they work differently to calm the overactive immune system. Research consistently shows they are highly effective at preventing VKC flares and are incredibly safe for long-term, daily use without the risks of glaucoma or cataracts [12][13].

What to expect when switching:

  • It takes time: Unlike steroids that work in a matter of days, immunomodulators may take several weeks to build up in the system and show their full protective effect [14][15].
  • They can sting: Many children experience a temporary stinging or burning sensation when these drops are applied [12]. This is a normal reaction and not a sign that the medication is harming the eye. Knowing to expect this discomfort can help you encourage your child to push through the transition.

By understanding this risk-benefit profile, you can feel confident in your doctor’s plan: using steroids briefly to stop emergencies, and relying on safer daily drops to protect your child’s vision long-term.

Common questions in this guide

Why do doctors limit the use of steroid eye drops for VKC?
Doctors limit steroid eye drops because long-term use can cause severe, vision-threatening complications like steroid-induced glaucoma and premature cataracts. They prefer to use steroids only briefly to stop severe flare-ups before switching to safer daily medications.
What is steroid-induced glaucoma?
Steroid-induced glaucoma is a dangerous spike in eye pressure caused by steroid use. It is a silent condition with no pain or redness, but if left unmonitored and untreated, it can permanently damage the optic nerve and cause irreversible vision loss.
What is pulse therapy for vernal keratoconjunctivitis?
Pulse therapy involves using a short, intense burst of steroid eye drops to aggressively calm intense inflammation and swelling during a severe VKC flare. Once the flare is under control, the medication is quickly tapered off to avoid long-term complications.
Are there safer long-term alternatives to steroid eye drops?
Yes, once a severe flare is managed, doctors typically switch to steroid-sparing immunomodulators like cyclosporine or tacrolimus. These drops are very safe for long-term, daily use, though they can temporarily sting upon application and take several weeks to reach full effect.
How can I help reduce the risks of steroid eye drops?
You can gently press on the inner corner of your child's eye near the nose for about a minute after applying the drop. This technique, called punctal occlusion, helps prevent the medication from draining into the rest of the body.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is our specific tapering schedule for this steroid pulse to safely bring down the inflammation?
  2. 2.Are we using a 'soft' steroid or a more potent one, and how does that affect how often we need to check eye pressure?
  3. 3.At what point in the treatment plan will we begin transitioning to a long-term maintenance drop like cyclosporine or tacrolimus?
  4. 4.How frequently should we schedule follow-ups to monitor intraocular pressure while on these drops?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Novel Insights in the Management of Vernal Keratoconjunctivitis (VKC): European Expert Consensus Using a Modified Nominal Group Technique.

    Dahlmann-Noor A, Bonini S, Bremond-Gignac D, et al.

    Ophthalmology and therapy 2023; (12(2)):1207-1222 doi:10.1007/s40123-023-00665-5.

    PMID: 36790673
  2. 2

    Case series of children with steroid-Induced glaucoma.

    Lam CS, Umi Kalthum MN, Norshamsiah MD, Bastion M

    Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia 2018; (13(3)):32-37.

    PMID: 30800232
  3. 3

    Commentary: Surgical outcomes in uveitic glaucoma and steroid-induced glaucoma in children: Between the two evils.

    Pillai MR, Balasubramaniam N

    Indian journal of ophthalmology 2022; (70(12)):4225-4227 doi:10.4103/ijo.IJO_2255_22.

    PMID: 36453319
  4. 4

    Pattern of steroid misuse in vernal keratoconjunctivitis resulting in steroid induced glaucoma and visual disability in Indian rural population: An important public health problem in pediatric age group.

    Sen P, Jain S, Mohan A, et al.

    Indian journal of ophthalmology 2019; (67(10)):1650-1655 doi:10.4103/ijo.IJO_2143_18.

    PMID: 31546501
  5. 5

    Steroid-induced glaucoma and childhood blindness.

    Gupta S, Shah P, Grewal S, et al.

    The British journal of ophthalmology 2015; (99(11)):1454-6 doi:10.1136/bjophthalmol-2014-306557.

    PMID: 26002945
  6. 6

    Seeing eye to eye: a modified Delphi method-based multidisciplinary expert consensus on the diagnosis and treatment of vernal keratoconjunctivitis.

    Ghiglioni DG, Bruschi G, Chiappini E, et al.

    European journal of pediatrics 2024; (183(11)):5053-5061 doi:10.1007/s00431-024-05776-0.

    PMID: 39325215
  7. 7

    Vernal Keratoconjunctivitis: A Systematic Review.

    Bruschi G, Ghiglioni DG, Cozzi L, et al.

    Clinical reviews in allergy & immunology 2023; (65(2)):277-329 doi:10.1007/s12016-023-08970-4.

    PMID: 37658939
  8. 8

    Therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials.

    Zhao M, He F, Yang Y, et al.

    European journal of hospital pharmacy : science and practice 2022; (29(3)):129-133 doi:10.1136/ejhpharm-2020-002447.

    PMID: 33144336
  9. 9

    Safety and efficacy of topical tacrolimus 0.03% in the management of vernal keratoconjunctivitis: a non-randomized controlled clinical trial.

    Eltagoury M, Abou Samra W, Ghoneim E

    Medical hypothesis, discovery & innovation ophthalmology journal 2022; (11(2)):52-63 doi:10.51329/mehdiophthal1446.

    PMID: 37641784
  10. 10

    NOVATIVE: A Phase II/III, Multicenter, Double-masked, Randomized Study of Cyclosporine A 0.05% and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients with Vernal Keratoconjunctivitis.

    Leonardi A, Pisella PJ, Benítez-Del-Castillo JM, et al.

    Clinical therapeutics 2023; (45(12)):1284-1288 doi:10.1016/j.clinthera.2023.09.022.

    PMID: 37872059
  11. 11

    Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials.

    Leonardi A, Doan S, Aragona P, et al.

    Eye (London, England) 2023; (37(11)):2320-2326 doi:10.1038/s41433-022-02342-6.

    PMID: 36564576
  12. 12

    Long-term use of topical tacrolimus ointment: a safe and effective option for the treatment of vernal keratoconjunctivitis.

    Müller GG, José NK, de Castro RS, de Holanda EC

    Arquivos brasileiros de oftalmologia 2019; (82(2)):119-123 doi:10.5935/0004-2749.20190026.

    PMID: 30698232
  13. 13

    Long-Term Clinical Outcome of Tacrolimus Skin Ointment (0.03%) for the Treatment of Vernal Keratoconjunctivitis: A Quasi-Experimental Study.

    Ali W, Alam Khan S, Ullah Khan F, et al.

    Cureus 2023; (15(12)):e50579 doi:10.7759/cureus.50579.

    PMID: 38226116
  14. 14

    Efficacy of Topical Cyclosporine 0.05% the Treatment of Vernal Keratoconjunctivitis.

    Subedi K, Sharma B, Shrestha S

    Nepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH 2020; (12(23)):39-47 doi:10.3126/nepjoph.v12i1.24489.

    PMID: 32799238
  15. 15

    A comparative study between ciclosporine A eye drop (2%) and tacrolimus eye ointment (0.03%) in management of children with refractory vernal keratoconjunctivitis.

    Heikal MA, Soliman TT, Abousaif WS, Shebl AA

    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2022; (260(1)):353-361 doi:10.1007/s00417-021-05356-0.

    PMID: 34453603

This page provides educational information about the side effects of VKC treatments. Always consult your pediatric ophthalmologist before changing or stopping your child's eye drop regimen.

Get notified when new evidence is published on Vernal keratoconjunctivitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.